Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007:2007:61038.
doi: 10.1155/2007/61038.

The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient

Affiliations
Review

The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient

Mara Lorenzi. Exp Diabetes Res. 2007.

Abstract

The polyol pathway is a two-step metabolic pathway in which glucose is reduced to sorbitol, which is then converted to fructose. It is one of the most attractive candidate mechanisms to explain, at least in part, the cellular toxicity of diabetic hyperglycemia because (i) it becomes active when intracellular glucose concentrations are elevated, (ii) the two enzymes are present in human tissues and organs that are sites of diabetic complications, and (iii) the products of the pathway and the altered balance of cofactors generate the types of cellular stress that occur at the sites of diabetic complications. Inhibition (or ablation) of aldose reductase, the first and rate-limiting enzyme in the pathway, reproducibly prevents diabetic retinopathy in diabetic rodent models, but the results of a major clinical trial have been disappointing. Since then, it has become evident that truly informative indicators of polyol pathway activity and/or inhibition are elusive, but are likely to be other than sorbitol levels if meant to predict accurately tissue consequences. The spectrum of abnormalities known to occur in human diabetic retinopathy has enlarged to include glial and neuronal abnormalities, which in experimental animals are mediated by the polyol pathway. The endothelial cells of human retinal vessels have been noted to have aldose reductase. Specific polymorphisms in the promoter region of the aldose reductase gene have been found associated with susceptibility or progression of diabetic retinopathy. This new knowledge has rekindled interest in a possible role of the polyol pathway in diabetic retinopathy and in methodological investigation that may prepare new clinical trials. Only new drugs that inhibit aldose reductase with higher efficacy and safety than older drugs will make possible to learn if the resilience of the polyol pathway means that it has a role in human diabetic retinopathy that should not have gone undiscovered.

PubMed Disclaimer

References

    1. Gabbay KH. The sorbitol pathway and the complications of diabetes. The New England Journal of Medicine. 1973;288(16):831–836. - PubMed
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine. 1993;329(14):977–986. - PubMed
    1. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 1999;22(supplement 1):S27–S31. - PubMed
    1. The Writing Team for the Diabetes Control & Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. The Journal of the American Medical Association. 2002;287(19):2563–2569. - PMC - PubMed
    1. Oates PJ. The polyol pathway and diabetic peripheral neuropathy. In: Tomlinson DR, editor. Neurobiology of Diabetic Neuropathy. vol. 50. London, UK: Academic Press; 2002. pp. 325–392. (International Review of Neurobiology). - PubMed

Publication types

LinkOut - more resources